Novo Nordisk patent-and-pricing narratives are everywhere - what's missing is the incremental detail
The Opportunity
This is routed as edge decay and the direction is MIXED, which is the right stance for a pricing/patent-expiration narrative in a high-visibility name: the same headline family can support both a bull story (durable demand, new access) and a bear story (pricing pressure, patent cliffs). In other words, there is no free informational edge left; the only edge is the incremental detail that changes cash-flow expectations.
The Timing
In a Bearish 72, high-crosswind regime, trading a mixed-direction, widely propagated story is a poor risk/reward proposition unless you have a discrete legal document (expiry date, litigation outcome) or a policy decision that markets have not yet internalised. Upstream routing says the edge window is closing, so the default posture should be AVOID until a document-level catalyst appears.
The Evidence
The upstream evidence bundle explicitly includes Tier-1 coverage (Reuters, Bloomberg, FT, The Guardian are in the 6B domain set), which is why this is spreading and decaying. Hydrated URLs are not provided for this signal in the payload; therefore the only safe evidentiary claim is mainstream propagation rather than contained discovery ( reuters.com , bloomberg.com , ft.com ). The absence of a singled-out primary patent/legal artefact in the payload is exactly why this stays MIXED and AVOID.